Hoffmann Peter, Bentley Phil, Sahota Pritam, Schoenfeld Heidi, Martin Lori, Longo Linda, Spaet Robert, Moulin Pierre, Pantano Serafino, Dubost Valerie, Lapadula Dan, Burkey Bryan, Kaushik Virendar, Zhou Wei, Hayes Michael, Flavahan Nick, Chibout Salah-Dine, Busch Steve
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.
Toxicol Pathol. 2014 Jun;42(4):684-95. doi: 10.1177/0192623313516828. Epub 2014 Jan 20.
The purpose of this article is to characterize skin lesions in cynomolgus monkeys following vildagliptin (dipeptidyl peptidase-4 inhibitor) treatment. Oral vildagliptin administration caused dose-dependent and reversible blister formation, peeling and flaking skin, erosions, ulcerations, scabs, and sores involving the extremities at ≥5 mg/kg/day and necrosis of the tail and the pinnae at ≥80 mg/kg/day after 3 weeks of treatment. At the affected sites, the media and the endothelium of dermal arterioles showed hypertrophy/hyperplasia. Skin lesion formation was prevented by elevating ambient temperature. Vildagliptin treatment also produced an increase in blood pressure and heart rate likely via increased sympathetic tone. Following treatment with vildagliptin at 80 mg/kg/day, the recovery time after lowering the temperature in the feet of monkeys and inducing cold stress was prolonged. Ex vivo investigations showed that small digital arteries from skin biopsies of vildagliptin-treated monkeys exhibited an increase in neuropeptide Y-induced vasoconstriction. This finding correlated with a specific increase in NPY and in NPY1 receptors observed in the skin of vildagliptin-treated monkeys. Present data provide evidence that skin effects in monkeys are of vascular origin and that the effects on the NPY system in combination with increased peripheral sympathetic tone play an important pathomechanistic role in the pathogenesis of cutaneous toxicity.
本文旨在描述维格列汀(二肽基肽酶-4抑制剂)治疗后的食蟹猴皮肤损伤情况。口服维格列汀导致剂量依赖性且可逆的水疱形成、皮肤脱皮和剥落、糜烂、溃疡、结痂以及在≥5mg/kg/天剂量时累及四肢的疮疡,以及在治疗3周后≥80mg/kg/天剂量时出现的尾巴和耳廓坏死。在受影响部位,真皮小动脉的中膜和内皮显示肥大/增生。通过提高环境温度可预防皮肤损伤形成。维格列汀治疗还可能通过增加交感神经张力导致血压和心率升高。在以80mg/kg/天的剂量用维格列汀治疗后,降低猴子足部温度并诱导冷应激后的恢复时间延长。体外研究表明,取自维格列汀治疗猴子皮肤活检的指动脉对神经肽Y诱导的血管收缩增加。这一发现与在维格列汀治疗猴子的皮肤中观察到的神经肽Y和神经肽Y1受体的特异性增加相关。现有数据提供了证据,表明猴子的皮肤效应源于血管,并且对神经肽Y系统的影响与外周交感神经张力增加相结合在皮肤毒性的发病机制中起重要的病理机制作用。